You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 341 Phase 1b/2 study of BXCL701, an oral activator of the systemic innate immunity pathway, combined with pembrolizumab (pembro), in men with metastatic castration-resistant prostate cancer (mCRPC)

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
341 Phase 1b/2 study of BXCL701, an oral activator of the systemic innate immunity pathway, combined with pembrolizumab (pembro), in men with metastatic castration-resistant prostate cancer (mCRPC)

 

Online download statistics by month:

Online download statistics by month: November 2020 to September 2024

AbstractFullPdf
Nov 2020175025
Dec 20202803
Jan 20212003
Feb 20213002
Mar 202140012
Apr 20215008
May 2021608
Jun 2021008
Jul 2021003
Aug 20210010
Sep 2021007
Oct 202140015
Nov 202170019
Dec 20214806
Jan 20221405
Feb 20224608
Mar 20223805
Apr 20226202
May 20223804
Jun 20223001
Jul 20221601
Aug 20224204
Sep 20223202
Oct 20223602
Nov 20222203
Dec 20222803
Jan 20234403
Feb 20236006
Mar 20233603
Apr 20232403
May 20232603
Jun 20233403
Jul 20232605
Aug 20232806
Sep 20233601
Oct 20234405
Nov 20232802
Dec 20234201
Jan 20242401
Feb 20242601
Mar 20243401
Apr 2024801
May 20243000
Jun 20244302
Jul 20241602
Aug 20243201
Sep 20243001
Total15820220